Biswajit Kundu

Dr. Biswajit Kundu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ATArindam Talukdar
Arindam Talukdar
BKBiswajit Kundu
Biswajit Kundu
DSDipayan Sarkar
Dipayan Sarkar
SGSunny Goon
Sunny Goon
MMMohabul Alam Mondal
Mohabul Alam Mondal

26 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
BKBiswajit Kundu
Biswajit Kundu
SDSzabolcs Dvorácskó
Szabolcs Dvorácskó
ABAbhishek Basu
Abhishek Basu
LPLenny Pommerolle
Lenny Pommerolle
KKKyu Ah Kim
Kyu Ah Kim
MIMalliga R. Iyer
Malliga R. Iyer
The inhibition of soluble epoxide hydrolase (sEH) can reduce the level of dihydroxyeicosatrienoic acids (DHETs) effectively maintaining endogenous epoxyeicosatrienoic acids (EETs) levels, resulting in the amelioration of inflammation and pain. Consequently, the development of sEH inhibitors has been a prominent research area for over two decades. In the present study, we synthesized and evaluated sulfonyl urea derivatives for their potential to inhibit sEH. These compounds underwent extensive in vitro investigation, revealing their potency against human and mouse sEH, with 4f showing the most promising sEH inhibitory potential. When subjected to lipopolysaccharide (LPS)-induced acute lung injury (ALI) in studies in mice, compound 4f manifested promising anti-inflammatory efficacy. We investigated the analgesic efficacy of sEH inhibitor 4f in a murine pain model of tail-flick reflex. These results validate the role of sEH inhibition in inflammatory diseases and pave the way for the rational design and optimization of sEH inhibitors based on a sulfonyl urea template.